Shinde, V., Koen, A. L., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., . . . Madhi, S. A. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Taylor & Francis Group.
Chicago Style (17th ed.) CitationShinde, Vivek, et al. Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 Recombinant Spike Protein Vaccine with Matrix-MTM Adjuvant (NVX-CoV2373) Versus a Primary Series in People Living with and Without HIV-1 Infection in South Africa: A Randomized Crossover Phase 2a/2b Trial. Taylor & Francis Group.
MLA (9th ed.) CitationShinde, Vivek, et al. Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 Recombinant Spike Protein Vaccine with Matrix-MTM Adjuvant (NVX-CoV2373) Versus a Primary Series in People Living with and Without HIV-1 Infection in South Africa: A Randomized Crossover Phase 2a/2b Trial. Taylor & Francis Group.